GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (OTCPK:ENZN) » Definitions » 6-1 Month Momentum %

ENZN (Enzon Pharmaceuticals) 6-1 Month Momentum % : -56.11% (As of Dec. 13, 2024)


View and export this data going back to 1984. Start your Free Trial

What is Enzon Pharmaceuticals 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-12-13), Enzon Pharmaceuticals's 6-1 Month Momentum % is -56.11%.

The industry rank for Enzon Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:

ENZN's 6-1 Month Momentum % is ranked worse than
85.37% of 1476 companies
in the Biotechnology industry
Industry Median: -7.78 vs ENZN: -56.11

Competitive Comparison of Enzon Pharmaceuticals's 6-1 Month Momentum %

For the Biotechnology subindustry, Enzon Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzon Pharmaceuticals's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Enzon Pharmaceuticals's 6-1 Month Momentum % falls into.



Enzon Pharmaceuticals  (OTCPK:ENZN) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzon Pharmaceuticals  (OTCPK:ENZN) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Enzon Pharmaceuticals 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016
Enzon Pharmaceuticals Inc is positioned as a public company acquisition vehicle, where the Company can become an acquisition platform and more fully utilize its net operating loss carryforwards and enhance stockholder value.
Executives
Randolph C Read director C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022
Jaffrey Adam Firestone director C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479
Family Fund Couchman other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jordan Bleznick director C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016
Pearce Michael Cooper other: See explanation of responses 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Harper Asset Management Llc other: See explanation of responses 2945 S CENTER GREEN CT, G215, BOULDER CO 80301
Brian James Harper other: See explanation of responses 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301
Myrexis, Inc. other: See Footnote 1 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020
Xstelos Corp. other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jonathan Couchman 10 percent owner, other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Carl C Icahn 10 percent owner C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160
Richard L Feinstein officer: VP-Finance and PFO
Jonathan Christodoro director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121